AT13387 in Treating Patients With Refractory Solid Tumors

DISEASE CHARACTERISTICS:

• Histologically confirmed solid tumor malignancy

  • Metastatic or unresectable disease for which no standard curative measures exist OR failed ≥ 1 line of standard therapy
• Measurable or evaluable disease

• Archived tumor tissue must be HER2/neu ≥ 1+ by IHC (expansion phase)

  • Disease amenable to biopsy

• No known brain metastases or carcinomatous meningitis

  • Brain metastatic disease that has remained stable for ≥ 2 months after treatment, without steroids or anti-seizure medications, allowed at the discretion of the principal investigator

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Life expectancy > 3 months
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN
• Creatinine < 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must agree to use adequate contraception (hormonal, barrier method of birth control, or abstinence) prior to, during, and for 2 months after completion of study
• Willingness to undergo pre- and post-treatment biopsies (expansion phase)

• No clinically significant intercurrent illnesses including, but not limited to, any of the following:

  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Uncontrolled cardiac arrhythmia
  • Psychiatric illness and/or social situations that would limit compliance with study requirements
• QTc > 450 msec (for men) or QTc > 470 msec (for women)

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since prior chemotherapy, radiotherapy, or biologic therapy (6 weeks for nitrosoureas or mitomycin C)
• At least 2 weeks since any prior drug in an exploratory IND/phase 0 study
• Recovered from prior toxicity or adverse events
• Concurrent bisphosphonates for any cancer allowed
• No concurrent combination antiretroviral therapy for HIV-positive patients